ChroMedX REPORTS on HEMOPALM DEVELOPMENT
ChroMedX Corp. (the "Company"), a developer of in vitro diagnostics and point-of-care testing (POCT) is pleased to report on the Company's HemoPalm development program.ChroMedX Completes Proof-of-Concept CO-Oximetry and Bilirubin Prototype Development
ChroMedX Corp.(the "Company"), a developer of in vitro diagnostics and point-of-care testing (POCT) devices is pleased to report the development of a proof-of-concept prototype of the Company's HemoPalm(TM) analyzer and associated cartridge for measuring CO-oximetry and bilirubin*.ChroMedX Engages Hochuen International Corp. for Improved Prototype Cartridge Production
ChroMedX Corp. (the "Company"), a developer of in vitro diagnostics and point-of-care testing (POCT) is pleased to report that it has engaged Hochuen International Corp. to produce an enhanced version of its prototype HemoPalm cartridges.ChroMedX Corp. Awarded New United States Patent on Ultra Filtration Technology
ChroMedX Corp. (the "Company"), a developer of in vitro diagnostics and point-of-care testing (POCT) is pleased to announce that the Company has been awarded a United States patent on its Ultra Filtration technology.HemoPalm Empowers First Responders and Physicians Where a Lab Is Not an Option
Each year, hundreds of thousands of patients come to the ER experiencing life threatening events such as possible carbon monoxide poisoning or heart attacks, attending doctors in a medical institution rely on the current standard blood gas analyzers to diagnose the oxygen-carrying capabilities of blood, blood gases and electrolytes. Normally, these type of tests are taken with an arterial blood sample (typically an artery in the arm), and are then sent off to a central lab, where a bench top unit uses spectroscopy and electrochemical sensor measurements to provide results. It can take hours to get the results.ChroMedX Collaborates with Biointerface Institute and Receives Grant
ChroMedX Corp. (the "Company"), a developer of in vitro diagnostics and point-of-care testing (POCT) is pleased to announce that it has entered into a collaboration with Dr. Leyla Soleymani of the Biointerface Institute of McMaster University and received an Engage Grant from NSERC (Natural Sciences and Engineering Research Council of Canada) to further HemoPalmTM biosensor development.ChroMedX Reports Testing of Key HemoPalm Analyzer Component
ChroMedX Corp. (the "Company"), a developer of in vitro diagnostics and point-of-care technologies is pleased to report that testing has commenced on the key spectroscopic component of the Analyzer of HemoPalm(TM) blood analysis device.ChroMedX Announces Completion of HemoPalm Prototype Cartridge
ChroMedX Corp. (the "Company") (CSE: CHX, OTC: MNLIF, Frankfurt: EIY2), a developer of in vitro diagnostics and point-of-care testing (POCT) is pleased to report the completion of the HemoPalmTM System Prototype Cartridge.ChroMedX Engages Polygenesis Corporation for Completion of HemoPalm(TM) Alpha
ChroMedX Corp, a developer of in vitro diagnostics and point-of-care testing (POCT) is pleased to announce the engagement of technology development and prototyping firm Polygenesis Corporation to continue the development of the HemoPalm biosensor array, a fundamental component of the HemoPalm system.ChroMedX Submits PCT Patent Application for HemoPalm(TM) Blood Analysis System
ChroMedX Corp(the "Company"), a developer of in vitro diagnostics and point-of-care testing (POCT) technologies is pleased to announce the filing of a PCT (Patent Cooperation Treaty) Patent Application pertaining to the HemoPalm(TM) Cartridge and Analyzer system called "Joint Spectroscopic and Biosensor System for Point-of-Care Testing" (PCT/CA2015/050455).